piper sandler:下调Biogen(BIIB.US)评级,由增持调整至中性评级,目标价由315.00美元调整至138.00美元。渤健公司(BIIB.US)公司简介:生物基因公司是一家生物制药公司,从事神经和神经退行性疾病的发现、开发和提供治疗。其产品包括治疗多发性硬化症的TECFIDERA、VUMERITY、AVONEX、PLEGRIDY、TYSABRI和FAMPYRA,治疗SMA的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.